• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?
【24h】

Do phosphodiesterase type 5 inhibitors protect against condom-associated erection loss and condom slippage?

机译：磷酸二酯酶5型抑制剂可防止与避孕套相关的勃起损失和避孕套打滑吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Some physicians prescribe phosphodiesterase type 5 inhibitors (PDE5i) for men who experience condom-associated erection difficulties with a view to increasing condom use and reducing risk of sexually transmitted infections. AIM: To examine whether the prevalence of erection-related condom problems differs between men using and not using PDE5i at the last condom-protected penile-vaginal (PVI) or penile-anal intercourse. METHODS: Seven hundred-five men who had used a male condom during the past 3 months for PVI were selected from a sample recruited through advertisement to an electronic mailing list for a large, internet-based, sexual-enhancement product company. An internet-based questionnaire posted in 2006 assessed condom-use errors and problems. MAIN OUTCOME MEASURES: Men who did and did not use PDE5i during the last time a condom was used were compared on: (i) erection loss while applying a condom; (ii) erection loss during sex while using a condom; (iii) condom slipped off during sex; (iv) delayed condom application (penetration of the vagina or anus prior to application of the male condom); (v) early condom removal (condom taken off and intercourse continued without it); (vi) "problem with the way the condom fit"; (vii) "problem with the way the condom felt"; and (viii) condom breakage. RESULTS: Controlling for age, marital status (yeso), and having children (yeso), PDE5i users, compared with nonusers, were: (i) three times more likely to report erection loss during sex while using a condom (adjusted odds ratio [AOR] = 3.21, 95% confidence interval [CI] = 1.40-7.39, P = 0.006); (ii) almost five times more likely to report the condom slipped off during sex (AOR = 4.75, 95% CI = 1.68-13.44, P = 0.003); and (iii) more than twice as likely to remove condoms before sex was over (AOR = 2.46, 95% CI = 1.09-5.56, P = 0.03). CONCLUSIONS: Physicians prescribing PDE5i may want to evaluate whether men are experiencing condom-associated erection difficulties and, if they are, consider titrating dosages and/or making referrals for psychosexual therapy and/or condom skills education.
机译：简介：一些医生为患有安全套相关勃起困难的男性开了5型磷酸二酯酶抑制剂（PDE5i），以期增加使用安全套并减少性传播感染的风险。目的：研究在上次使用避孕套保护的阴茎阴道（PVI）或阴茎-肛门性交中使用和不使用PDE5i的男性之间是否存在与勃起相关的避孕套问题。方法：从一个大型的基于互联网的性增强产品公司的广告招募样本中，选择了在过去3个月中使用过男用避孕套进行PVI的755名男性。 2006年发布的基于互联网的调查表评估了避孕套使用中的错误和问题。主要观察指标：比较在上次使用安全套期间使用和未使用PDE5i的男性的以下方面：（i）使用安全套时勃起损失; （ii）使用安全套时性生活中的勃起损失; （iii）避孕套在性交时脱落; （iv）避孕套延迟使用（在使用男性避孕套之前先穿透阴道或肛门）; （v）尽早取出避孕套（摘下避孕套，没有避孕套继续进行性交）; （vi）“安全套使用方式的问题”; （vii）“避孕套的感觉有问题”; （viii）避孕套破裂。结果：控制年龄，婚姻状况（是/否）和有孩子（是/否）的PDE5i使用者与非使用者相比：（i）使用安全套时发生性行为时勃起损失的可能性高三倍（调整后的优势比[AOR] = 3.21，95％置信区间[CI] = 1.40-7.39，P = 0.006）; （ii）报告说避孕套在性交中脱落的可能性几乎是其的五倍（AOR = 4.75，95％CI = 1.68-13.44，P = 0.003）; （iii）在性生活结束前移除安全套的可能性是其两倍多（AOR = 2.46，95％CI = 1.09-5.56，P = 0.03）。结论：开具PDE5i的医师可能希望评估男性是否正在遇到与安全套相关的勃起困难，如果是，则考虑调整剂量和/或转介进行心理性治疗和/或安全套技能教育。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号